Vmbook Online ordering

Icons

I'm glad to assist you with your inquiry about the company "Icons" with the stock symbol "BNNR" that is traded on the OTC Markets Group's OTCQB venture marketplace, which is affiliated with but not identical to a national stock exchange.

Border-Inner Acquisition Corp. (OTCQB: BNNR) is a blank check company, also known as a special purpose acquisition company (SPAC), incorporated in Delaware in December 2018. SPACs are publicly traded companies that are formed to raise capital through an initial public offering (IPO) for the purpose of acquiring or merging with an existing company.

On October 21, 2021, Border-Inner Acquisition Corp. announced that it had entered into a definitive agreement for a business combination with Icon plc, a global provider of advanced drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The proposed transaction is expected to close in the first half of 2022, subject to certain closing conditions. Upon closing of the transaction, the combined company will operate under the Icon name and will continue to be listed on the NASDAQ Stock Market under the new ticker symbol "ICLR".

Icon is a global provider of drug development solutions and services, with a focus on clinical research, consulting, and laboratory services. The company is headquartered in Dublin, Ireland and has operations in 47 countries. Icon employs approximately 15,000 people.

In terms of financial performance, Icon has reported strong revenue and earnings growth over the past few years. In 2020, Icon reported total revenues of $3.7 billion, representing an increase of 8% compared to the previous year. Net income for the year was $266.8 million, up from $223.6 million in 2019. Icon's backlog of future business at the end of 2020 was $8.3 billion, up from $7.2 billion at the end of 2019, reflecting the company's continued growth and strong demand for its services.

Overall, Border-Inner Acquisition Corp.'s proposed business combination with Icon plc represents a compelling opportunity for investors to gain exposure to a leading global provider of drug development solutions and services. With its strong financial performance and growing backlog of future business, Icon is well-positioned for continued growth and success in the coming years.